Foundayo (orforglipron) and Wegovy tablets (semaglutide) are daily GLP-1 pills approved for weight management in eligible U.S. adults. The clearest everyday difference is food timing. Foundayo can be taken with or without food. Wegovy tablets need an empty stomach in the morning and a wait before breakfast, other drinks or oral medicines. Separate obesity trials showed that each pill helped people lose weight compared with placebo. A direct trial in diabetes tested a different semaglutide dose and answered a different question.
Which oral product are you comparing?
| Daily pill | Active ingredient | U.S. approved purposes |
|---|---|---|
| Foundayo | Orforglipron, a nonpeptide GLP-1 medicine | Long-term weight management for adults with obesity or overweight and at least one weight-related condition |
| Wegovy tablets | Semaglutide, a peptide GLP-1 medicine | Long-term weight management in the same broad adult population. Also reduces the risk of major cardiovascular events for adults with established cardiovascular disease and either obesity or overweight. |
Both weight-management indications include a reduced-calorie diet and increased physical activity. If your clinician says “oral semaglutide,” ask for the brand. Rybelsus and Ozempic tablets are oral semaglutide products for type 2 diabetes, with their own strengths and instructions. The weight-management comparison here is with Wegovy tablets. Foundayo U.S. label · Wegovy U.S. label · FDA label for Ozempic tablets and Rybelsus
Which pill would fit your morning?
Foundayo: Take one whole tablet daily, with or without food. Swallow it whole. Do not break, crush or chew it. Wegovy tablets: Take one whole tablet in the morning on an empty stomach with up to 4 ounces of plain water. Do not split, crush, chew or dissolve it. Wait at least 30 minutes before food, other drinks or other oral medicines. Both labels say to take no more than one tablet per day. Foundayo label, section 2.1 · Wegovy label, section 2.1
Suppose you take a prescription at 6:30 a.m. and eat before catching a 6:45 bus. Adding Wegovy to the same 6:30 pill routine puts it too close to the other medicine and breakfast. A 6:00 a.m. Wegovy dose would clear Wegovy’s own 30-minute interval by 6:30. Ask the pharmacist whether that order also meets the other medicine’s requirements. If an earlier time is impractical, say so. Foundayo’s flexible meal timing may remove that obstacle, and the pharmacist can still check for interactions. For the steps specific to semaglutide tablets, see how to take oral Wegovy.
What do the obesity trials show about weight loss?
Each row compares the pill with its own placebo group. Both trials enrolled adults with obesity, or overweight with a qualifying condition, without diabetes. Participants also received diet and activity support.
| U.S. prescribing information | Tested daily regimen | Average weight loss | Placebo in the same trial |
|---|---|---|---|
| Foundayo, Trial 1 at 72 weeks | Orforglipron 17.2 mg, reported as the marketed tablet strength | 11.1% | 2.1% |
| Wegovy tablets, Study 7 at 64 weeks | Oral semaglutide 25 mg | 13.6% | 2.4% |
Both pills improved average weight loss versus their respective placebos. The groups had different follow-up times and trial methods, so subtracting 11.1% from 13.6% does not estimate an advantage you’d gain by switching. Older orforglipron results may list a research capsule strength. Check the U.S. tablet label for the dose on your actual prescription. Foundayo prescribing information, section 14 · Wegovy prescribing information, section 14.2
If there was a head-to-head trial, why can’t it settle the obesity comparison?
ACHIEVE-3 tested the drugs for type 2 diabetes inadequately controlled with metformin. Over 52 weeks, the investigators compared daily orforglipron at investigational 12 mg or 36 mg with semaglutide tablets at 7 mg or 14 mg. Orforglipron reduced HbA1c more at the tested doses. Gastrointestinal adverse events and stops due to adverse events were more common in the orforglipron groups. The trial is directly useful for understanding those diabetes regimens. The semaglutide comparison did not include the 25 mg Wegovy tablet for weight management, and the primary outcome was HbA1c. ACHIEVE-3 trial publication
What could change which pill is a better fit?
If the reason for treatment includes reducing cardiovascular risk and you have established cardiovascular disease, ask which indication applies to you. If meal timing is the obstacle, bring your real schedule. If another medicine could interact, bring its name and dose. For example, the Foundayo label advises people taking oral hormonal contraception to use a non-oral method or add a barrier method for 30 days after starting and 30 days after each dose increase. Both labels advise against using the pill alongside another GLP-1 receptor agonist. Ask which exact prescription, medication schedule and follow-up you’d leave with before comparing headline averages or prices. Foundayo prescribing information, sections 1 and 8.3 · Wegovy prescribing information, section 1

About the author
Maya Lee
Glowise Senior GLP-1 Content Editor
Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.
She helps readers ask better questions and keep the details relevant to a care conversation together.
See more Glowise on Google
Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.



